Skip to content
Peptigraph home

CJC-1295

GHRH analog. CJC-1295 is not FDA approved for any use.

Also called:CJCmod GRFGRF 1-29
Medically reviewed by Juan Pablo Frías, MD · · DisclosureUpdated Strongest evidence: Human RCT evidence, 4 of 4
StatusNot FDA approved · research chemicalProhibited by WADA (S2.2.4)Full legal history

Key facts

Class
GHRH analog
Also called
CJC, mod GRF
Vial sizes sold
2 mg, 5 mg, 10 mg
Community-reported sizes
Half-life
Not found
No published half-life found (PubMed search, 11 Oct 2026)
FDA status
Not approved
research chemical
WADA
Prohibited (S2.2.4)
In and out of competition
Everything on CJC-1295

CJC-1295 guides

Vial and dose sizes
Researched for

Evidence at a glance

Human and animal counts are PubMed records from our evidence ledger (search counts, not studies we reviewed). The grade is the strongest design among the studies we summarised for that goal: a human randomized trial outweighs any number of animal studies.

CJC-1295: studies by condition
ConditionHuman studiesAnimal studiesStudies we summarisedEvidence grade
Muscle growth112Human observational evidence, 3 of 4Substance use & misuse 2016, PMID 26771670
Weight loss211Human observational evidence, 3 of 4Substance use & misuse 2016, PMID 26771670
Sleep201Human observational evidence, 3 of 4Substance use & misuse 2016, PMID 26771670
Energy000No graded study for this goal
Hormone balance102Human RCT evidence, 4 of 4The Journal of clinical endocrinology and metabolism 2006, PMID 16352683

Grades follow our evidence scale. Summarised studies come from our evidence file, each quote checked against the abstract or label.

A long-acting GHRH analogue

The paper behind it used in vivo bioconjugation to serum albumin as a way to extend a peptide's plasma half-life.[9]

In the rat bioconjugate study, CJC-1295 was the best compound, with a 4-fold increase in GH area under the curve over 2 hours compared with hGRF(1-29).[9]

All of the human data are in healthy volunteers

In two randomized placebo-controlled trials in healthy adults, hormone levels were the outcome: a single injection raised mean plasma GH 2- to 10-fold for 6 days or more and IGF-I 1.5- to 3-fold for 9-11 days.[5]

Pulses of GH persisted during treatment: trough levels rose while the frequency and magnitude of pulses were unaltered.[10]

The only evidence on why people use it is a forum study of women, which records weight loss, muscle, skin, sleep and injury healing as stated motives. These are motives, not measured results.[4]

Regulatory path

FDA lists no approved CJC-1295 product.[2]

FDA's safety-risk table names immunogenicity as a concern for compounded CJC-1295 by some routes.[3]

WADA names CJC-1295 as an example of GHRH analogues on its prohibited list.[1]

Compared with

Common stacks

CJC-1295 is often sold pre-mixed or combined with other peptides. No controlled study has tested these combinations; the pages below cover the math and what each part has been studied for.

Common questions

Is CJC-1295 FDA approved?

No. CJC-1295 is not FDA approved for any use.

Is CJC-1295 banned in sport?

Yes. Prohibited by WADA (S2.2.4), so it is prohibited at all times for tested athletes.

How much water goes in a 10 mg vial?

That choice only changes the concentration. With 2 mL, the vial is 5 mg/mL. The calculator converts any amount to syringe units. It does the math only and does not suggest a dose.

What is CJC-1295?

A long-acting analogue of growth hormone-releasing hormone, tested in healthy adults for hormone effects.[5]

What does CJC-1295 do?

In trials it raised growth hormone and IGF-I levels for days; those trials measured hormone levels rather than weight, muscle or sleep.[5]

Is there oral CJC-1295?

The trials used subcutaneous injection; no human study of an oral form was found.[5]

Sources

  1. 1World Anti-Doping Code International Standard Prohibited List 2026World Anti-Doping Agency · 2026wada-ama.orgAccessed 2 Oct 2026
  2. 2United States: No FDA-approved product found: Drugs@FDA (openFDA) search for active ingredient "cjc-1295" returned no matches on 2 Oct 2026.U.S. Food and Drug Administration · 2026api.fda.govAccessed 2 Oct 2026
  3. 3US compounding: CJC-1295 appears in FDA's table of bulk drug substances previously in category 2 and withdrawn by the nominators.U.S. Food and Drug Administration · 2026fda.govAccessed 2 Oct 2026
  4. 4Netnography of Female Use of the Synthetic Growth Hormone CJC-1295: Pulses and Potions.Substance use & misuse · 2016PMID 26771670Accessed 2 Oct 2026
  5. 5Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults.The Journal of clinical endocrinology and metabolism · 2006PMID 16352683Accessed 2 Oct 2026
  6. 6PubMed search: ("CJC-1295"[tiab] OR CJC1295[tiab]) (33 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  7. 7PubMed search: ("CJC-1295"[tiab] OR CJC1295[tiab]) AND (half-life[tiab] OR pharmacokinetic*[tiab]) (7 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  8. 8PubMed search: ("CJC-1295"[tiab] OR CJC1295[tiab]) AND (adverse[tiab] OR "side effect*"[tiab] OR safety[tiab] OR tolerab*[tiab] OR toxicity[tiab] OR "case report"[pt]) (11 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 11 Oct 2026
  9. 9Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog.Endocrinology · 2005PMID 15817669Accessed 2 Oct 2026
  10. 10Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog.The Journal of clinical endocrinology and metabolism · 2006PMID 17018654Accessed 2 Oct 2026

Found an error? Report a correction.